Stem Cell Theranostics

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Stem Cell Theranostics
Private
IndustryBiotechnology
FounderAndrew Lee, Joseph Wu, Robert C. Robbins, Divya Nag
Headquarters,
Websitewww.sctheranostics.com Edit this on Wikidata

Stem Cell Theranostics is a privately held biotech company based out of Redwood City, California that provides drug companies with a method to more accurately predict cardiotoxicity and cardiovascular drug efficacy.[1]

History[edit]

Stem Cell Theranostics was founded by graduate student Andrew S. Lee, Professor Joseph C. Wu, Professor Robert C. Robbins, and undergraduate student Divya Nag. It was one of the first med tech startup to come out of the StartX incubator program. The company uses technology developed at Stanford,[2][3] to create a "clinical trial in a dish" drug screening platform, which reduces the risk of drug development.[4] The company currently works with drug discovery and biotechnology companies to use patient-specific induced pluripotent stem cells for development of novel therapeutics.[5]

References[edit]

  1. ^ Deanna Pogorelc. "Merck and J&J back StartX; "clinical-trial-in-a-dish" biotech wows at Demo Day". MedCity News. Retrieved 11 November 2014.
  2. ^ Krista Conger. "Scientists show that lab-made heart cells can be ideal model for disease research, drug testing". News Center. Retrieved 11 November 2014.
  3. ^ Krista Conger. "Researchers use stem cells to pinpoint cause of common type of sudden cardiac death". News Center. Retrieved 11 November 2014.
  4. ^ "Stem Cell Theranostics' clinical trial in a dish". Silicon Valley Business Journal. 29 March 2013. Retrieved 11 November 2014.
  5. ^ "The Experiment Begins: Y Combinator Admits First Biotech Startups". Xconomy. Retrieved 11 November 2014.

External links[edit]